Entries by BioSpace

, , , , , , , , ,

Congressional Report Claims Emergent Mishap Destroyed 400 Million Doses of J&J Vaccine

Just as Emergent BioSolutions looked to be making some headway in course corrections following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine, new information indicates the Maryland-based company sought to hide the deficiencies from federal regulators, all while touting its manufacturing capabilities, according to a BioSpace article.

, , , , , , , , , , , ,

Takeda Drops One Hunter Syndrome Therapeutic, Puts Faith in Another

In the company’s financial results for 2021 released on May 11, Takeda announced the decision to discontinue the development of TAK-609, a therapeutic for Hunter Syndrome. Additionally, Takeda is collaborating with JCR Pharmaceuticals in another therapeutic attempt for the condition.

, , , , , , ,

More durable, broader spectrum boosters needed against COVID-19

Current COVID-19 booster shots have a problem: they last only about four months and appear to have limited efficacy in a vaccinated population. Clearly, a more durable, more efficacious vaccine is needed, but what should it be? The scientific community has not reached a consensus, according to BioSpace.

, , , , , ,

AstraZeneca, Sanofi’s positive RSV data shows 80% reduction in infants

AstraZeneca and Sanofi’s Phase III and Phase IIb clinical trials investigating the efficacy of nirsevimab, measured through the development of secondary infections, are impressing the pharma community with positive prespecified pooled analysis results. The data shows 79.5 percent efficacy in the prevention of lower respiratory tract infections, caused by infection of the respiratory syncytial virus (RSV).

, , , , , , , , , , , ,

Cortexyme Charts New Course with Acquisition of Rare Disease Player

Cortexyme, a company focusing on treatments for degenerative diseases, entered into a deal to acquire Novosteo, which plays in the rare disease space. Once the deal is finalized, the merged companies will operate under the name Quince Therapeutics and trade under the ticker symbol QNCX.

, , , , , , , , , , , , , , , , ,

Eisai, Biogen take another step toward potential approval of Alzheimer’s drug

Eisai and Biogen completed the rolling submission of a Biologics License Application for their proposed Alzheimer’s disease drug to the U.S. Food and Drug Administration.